Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation and one abstract as an oral presentation at CHEST 2025 in Chicago, Illinois, October 19-22. The Company will also host a Learning Theatre titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis” at the meeting which is open to all registered conference attendees.

CHEST 2025 Posters, Oral Session and Learning Theater

Savara Presentations

Oral Presentation Title: Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session Title: Innovations in Assessment and Treatment of Fibrosing Lung Disease
Session ID: 4053
Date/Time of Presentation Session: October 21, 2025, 10:56-11:00 AM CDT
Location: Exhibit Hall Rapid Fire 3A, McCormick Place, Chicago
Presenter: Cormac McCarthy, M.D., Ph.D., FRCPI, Associate Professor of Medicine at the University College Dublin (UCD) and Consultant Respiratory Physician at St. Vincent’s University Hospital, Dublin, Ireland

Poster Title: Relationship Between Pulmonary Gas Transfer, Respiratory Health-Related Quality of Life (HRQoL), Exercise Capacity, and Surfactant Burden in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session Title: Diffuse Lung Disease Scientific Abstract Posters (D)
Date/Time of Poster Discussion Session: October 22, 2025, 10:20-11:05 AM CDT
Poster Number: 4260
Location: Poster Hall Exhibit, McCormick Place, Chicago
Presenter: Bruce Trapnell, M.D., Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine

TrilliumBiO Presentation

Poster Title: Development of a Dried Serum Assay for the Detection of GM-CSF Antibodies to Aid in the Diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session Title: Diffuse Lung Disease Scientific Abstract Posters (D)
Poster Number: 4257
Date/Time of Poster Presentation Session: October 22, 2025, 10:20-11:05 AM CDT
Location: Poster Hall Exhibit, McCormick Place, Chicago
Presenter: Eagappanath Thiruppathi, Ph.D., Director, Test and Method Development, TrilliumBiO

Savara Learning Theater

Title: Advances in Autoimmune Pulmonary Alveolar Proteinosis
Description: Kevin Davidson, M.D., FCCP, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, signs and symptoms, diagnosis and management, and burden of illness.